PURE Bioscience PURE, creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fourth quarter and fiscal year ended July 31, 2010 (“Fiscal 2010”).
Fiscal 2010 total revenues of $1,436,000, including licensing fees, increased by 97% over revenues of $728,300 in the year ended July 31, 2009 (“Fiscal 2009”). The net loss for Fiscal 2010 was $6,760,300, or $0.20 per share, compared with a loss of $7,067,300, or $0.23 per share, in Fiscal 2009.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in